Description
Product details
VILDIABATE M 500 Metformin (500mg)SR, Vildagliptin (50mg) Introduction Type 2 diabetes management can be complex, requiring a regimen that effectively controls blood glucose levels while minimizing side effects and enhancing patient adherence. VILDIABATE M 500, which combines Metformin SR (500mg) with Vildagliptin (50mg), provides a potent dual therapy that targets key aspects of diabetes control. This article explores the benefits, mechanisms of action, and clinical advantages of using VILDIABATE M 500 for managing Type 2 diabetes. Understanding the Components of VILDIABATE M 500 Metformin SR (500mg) Metformin, a cornerstone in diabetes treatment, primarily works by reducing hepatic glucose production and improving insulin sensitivity in muscle and fat tissues. The sustained-release (SR) formulation allows for a gradual release of the medication, minimizing gastrointestinal side effects and providing a stable, prolonged effect, which is crucial for maintaining consistent blood glucose levels throughout the day. Vildagliptin (50mg) Vildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhancing the body's natural ability to control blood sugar levels post-meal. It works by inhibiting the enzyme that breaks down incretin hormones, thereby increasing their availability. Incretins help increase insulin release and decrease glucagon production in a glucose-dependent manner, effectively reducing postprandial glucose spikes. Synergistic Benefits for Diabetes Management Comprehensive Glycemic Control VILDIABATE M 500 offers a comprehensive approach to managing blood glucose by targeting both fasting and postprandial levels. Metformin addresses fasting glucose by reducing liver glucose output and improving insulin sensitivity, while Vildagliptin controls postprandial spikes by enhancing the incretin effect. Minimized Risk of Hypoglycemia One of the significant benefits of VILDIABATE M 500 is its low risk of causing hypoglycemia. Both Metformin and Vildagliptin do not typically induce hypoglycemia as they do not stimulate excessive insulin secretion. This makes VILDIABATE M 500 a safer option for patients, especially the elderly and those with renal impairment. Weight Management Another advantage of VILDIABATE M 500 is its neutral impact on weight. Metformin has been known to aid in weight loss or maintain a neutral weight profile, and Vildagliptin does not contribute to weight gain. This aspect is particularly crucial in diabetes management, where weight control is often a key component of the overall treatment plan. Ideal Candidates for VILDIABATE M 500 VILDIABATE M 500 is particularly suitable for individuals with Type 2 diabetes who: Require an effective regimen to manage both fasting and postprandial blood glucose levels. Are concerned about the risks associated with hypoglycemia from other diabetes therapies. Need a medication regimen that supports weight management. For further information: EMAIL: info@sterispharma.com / contact@sterispharma.com CALL/WHATSAPP:: 7877551268, 8209542042, 8955945010, 6377716668 https://www.sterisonline.com/product/vildiabate-m-500-133454
